Biotech
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Del.icio.us
- Digg
- StumbleUpon
-
PLAY BEAT THE STREET GAME NOW
A Food and Drug Administration advisory panel voted 17-to-3 Tuesday to recommend the regulatory agency not grant wider approval for Cephalon's CEPH pain treatment Fentora on the premise that such an expansion could increase the potential for drug abuse. The drug is currently approved to treat breakthrough pain, or severe pain in cancer patients who are already taking prescription opioids. But Cephalon was seeking to expand the approved uses to include chronic pain in non-cancer patients. The FDA isn't required to follow the recommendations of advisory panels, but it usually does. Cephalon shares were halted from trading Tuesday ahead of the FDA panel vote.
The biotech company trounces Wall Street expectations for the first quarter on sales gains of Nexavar.
The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.
See who made what calls.
3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA
TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.
Take-Two's latest hit receives a perfect score from industry reviewers.
- Cramer's 'Mad Money' Recap: Mad Money's Rally Playbook
- The Polycarbonate Price Cut
- CalPERS Pushes for Clean House at Standard Pacific
- Investing in China: What You Need to Know
- Coming Week: 'Glimmer of Hope'
- Top Stocks With Insider Buying, Buybacks
- New Solar ETF Helps Spread Sector's Risk
- Feuerstein's Biotech-Stock Mailbag
- Need to Own Energy? Here's How to Do It
- My Company Doesn't Provide Health Insurance (Gulp!)
Sponsored by:
RSS
